ITM to Participate in Upcoming Investor Conferences
11. November 2024 05:00 ET
|
ITM Isotope Technologies Munich SE
Garching / Munich, November 11, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced its participation in two upcoming industry investor...
ITM, TUM und das TUM Universitätsklinikum unterzeichnen eine neue Rahmenvereinbarung zur Entwicklung innovativer radiopharmazeutischer Krebstherapien
24. Oktober 2024 05:00 ET
|
ITM Isotope Technologies Munich SE
Neufahrn / Garching / München, 24. Oktober 2024 – ITM Isotope Technologies Munich SE (ITM), ein führendes radiopharmazeutisches Unternehmen, die Technische Universität München (TUM) und das TUM...
ITM, TUM, and TUM University Hospital Sign New Framework Agreement to Advance Innovative Radiopharmaceutical Cancer Treatments
24. Oktober 2024 05:00 ET
|
ITM Isotope Technologies Munich SE
Neufahrn / Garching / Munich, Germany, October 24, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, the Technical University of Munich (TUM) and the TUM...
ITM and NTP Strengthen Global Radioisotope Production Capacities by Renewing their Technology License Agreement and Signing a Manufacturing and Supply Agreement for n.c.a. Lutetium-177
18. Oktober 2024 05:00 ET
|
ITM Isotope Technologies Munich SE
Extension of 2012 agreement grants NTP the rights to manufacture and distribute non-carrier-added Lutetium-177 (n.c.a. 177Lu)Companies enter into an additional manufacturing and supply...
ITM, Helmholtz Munich and University Hospital Münster Announce First Patient Dosed in Phase I Investigator-Initiated Glioblastoma Trial
23. April 2024 05:00 ET
|
ITM Isotope Technologies Munich SE
A Novel Therapeutic Approach to Treatment using ITM-31 Garching/Munich, Munich and Münster, April 23, 2024 – The Departments of Neurosurgery and Nuclear Medicine at the University...
ITM and Alpha-9 Oncology Announce Global Supply Agreement to Support Alpha-9’s Clinical Radiopharmaceutical Development Program
30. Januar 2024 07:00 ET
|
ITM Isotope Technologies Munich SE
GARCHING / MUNICH, Germany and VANCOUVER, British Columbia, January 30, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Alpha-9 Oncology (Alpha-9),...
ITM to Present at the 42nd Annual J.P. Morgan Healthcare Conference
21. Dezember 2023 08:00 ET
|
ITM Isotope Technologies Munich SE
Garching / Munich, Germany, December 21, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that CEO, Steffen Schuster and CFO, Dr. Klaus...
ITM to Present at the 41st Annual J.P. Morgan Healthcare Conference
03. Januar 2023 10:30 ET
|
ITM Isotope Technologies Munich SE
Garching / Munich, January 03, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that CEO Steffen Schuster and CFO Dr. Klaus Maleck will...
ITM Signs Clinical Supply Agreement with Y-mAbs for n.c.a. Lutetium-177
21. Juli 2022 05:21 ET
|
ITM Isotope Technologies Munich SE
ITM to supply its medical radioisotope, no-carrier-added Lutetium-177, for the clinical development of Y-mAbs’ Targeted Radionuclide Therapy candidate GD2-SADA: 177Lu-DOTA Complex for GD2-positive...
ITM: New Isotope Production System at Bruce Power Successfully Produces First Medical Isotope
21. Juni 2022 11:45 ET
|
ITM Isotope Technologies Munich SE
First-of-a-kind Isotope Production System continues to progress towards commercial, industrial-scale production of medical isotopes for cancer therapeutics ONTARIO, CANADA, and MUNICH, GERMANY – June...